SCHEMBL630362

SCHEMBL630362

COC(=O)c1ncncc1Br

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.43
MAPK1 P28482 2/20 0.37
ALDH1A1 P00352 2/20 0.37
ATM Q13315 1/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
CSNK2A1 P68400 1/20 0.36
NTRK1 P04629 1/20 0.36
KDM4E B2RXH2 2/20 0.35
GLA P06280 1/20 0.35
GAA P10253 1/20 0.35
CYP1A2 P05177 1/20 0.34
CYP2C19 P33261 1/20 0.34
TSHR P16473 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29574660 1.00 NPSR1 (0.43) NPSR1MAPK1ALDH1A1ATML3MBTL1
SCHEMBL11536944 0.81 GABRG2 (0.42) NPSR1MAPK1ALDH1A1KDM4ECYP1A2
SCHEMBL13943352 0.79 NPSR1 (0.45) NPSR1MAPK1ALDH1A1ATML3MBTL1
SCHEMBL30143994 0.79 NPSR1 (0.45) NPSR1MAPK1ALDH1A1ATML3MBTL1
SCHEMBL629032 0.78 HCAR2 (0.44) NPSR1ALDH1A1L3MBTL1NTRK1KDM4E
SCHEMBL30978924 0.78 HCAR2 (0.44) NPSR1ALDH1A1L3MBTL1NTRK1KDM4E
SCHEMBL1114935 0.78 NPSR1 (0.43) NPSR1MAPK1ALDH1A1ATML3MBTL1
SCHEMBL11527908 0.78 NPSR1 (0.43) NPSR1MAPK1ALDH1A1ATML3MBTL1
SCHEMBL15228341 0.78 NTRK1 (0.43) NTRK1
SCHEMBL7456714 0.78 ALDH1A1 (0.50) NPSR1MAPK1ALDH1A1ATML3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260049074-A1 THIADIAZOLYL DERIVATIVES IDEAYA BIOSCIENCES, INC. (US) 2026-02-19 US disclosed
US-12509454-B2 Thiadiazolyl derivatives IDEAYA BIOSCIENCES, INC. (US) 2025-12-30 US disclosed
EP-4594318-A1 AKT1 MODULATORS Alterome Therapeutics, Inc. (US) 2025-08-06 EP disclosed
EP-4584265-A1 NOVEL COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES THEREOF Cambridge Enterprise Limited (GB) 2025-07-16 EP disclosed
US-20250092040-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. 2025-03-20 US disclosed
US-20240239797-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. 2024-07-18 US disclosed
US-20240239797-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. 2024-07-18 US disclosed
US-11999730-B1 AKT1 modulators ALTEROME THERAPEUTICS, INC. (US) 2024-06-04 US disclosed
US-20240174667-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. 2024-05-30 US disclosed
WO-2024073371-A1 AKT1 MODULATORS ALTEROME THERAPEUTICS, INC. (US) 2024-04-04 WO disclosed
WO-2009097014-A2 THERAPEUTIC KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-08-06 WO disclosed
EP-2061765-A2 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS Cylene Pharmaceuticals, Inc. (US) 2009-05-27 EP disclosed
US-20090105233-A1 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-04-23 US disclosed
US-20090105233-A1 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-04-23 US disclosed
US-20090105233-A1 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-04-23 US disclosed
US-20090093465-A1 THERAPEUTIC KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-04-09 US disclosed
US-20090093465-A1 THERAPEUTIC KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-04-09 US disclosed
US-20090093465-A1 THERAPEUTIC KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-04-09 US disclosed
WO-2008028168-A2 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2008-03-06 WO disclosed
WO-2008028168-A2 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2008-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239797-A1 AKT1 MODULATORS AKT1S1, AKT1, AKT2 NPSR1 4796/4885MAPK1 124/4885ALDH1A1 4692/4885
US-20260049074-A1 THIADIAZOLYL DERIVATIVES POLH, POLM, POLD1 NPSR1 4672/4885MAPK1 4035/4885ALDH1A1 2481/4885
US-20090093465-A1 THERAPEUTIC KINASE MODULATORS PACSIN2, CKS1B, CSNK1A1 NPSR1 2942/4885MAPK1 255/4885ALDH1A1 4513/4885
US-20250092040-A1 AKT1 MODULATORS AKT1S1, AKT1, AKT2 NPSR1 4796/4885MAPK1 124/4885ALDH1A1 4692/4885
US-20090105233-A1 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS PACSIN2, TNKS, PARP1 NPSR1 3655/4885MAPK1 522/4885ALDH1A1 3529/4885
US-11999730-B1 AKT1 modulators AKT1S1, AKT1, AKT2 NPSR1 4796/4885MAPK1 124/4885ALDH1A1 4692/4885
US-12509454-B2 Thiadiazolyl derivatives POLD1, POLQ, DNA2 NPSR1 4847/4885MAPK1 2841/4885ALDH1A1 1747/4885
US-20240174667-A1 AKT1 MODULATORS AKT1S1, AKT1, AKT2 NPSR1 4796/4885MAPK1 124/4885ALDH1A1 4692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.